SRT3.DE Sartorius AG XETRA 03 Feb 2026: Q4 miss trims guidance, watch margins

SRT3.DE stock slid to €230.90 intraday on 03 Feb 2026 after Sartorius AG reported Q4 results below expectations. The surprise miss pushed the share price down €4.90 or -2.08% today on XETRA in Germany. Investors are parsing weaker margins, a cautious management outlook, and still-high leverage. We review the numbers, valuation, and short-term trading signals to show why margins and guidance will steer the next moves for Sartorius AG (SRT3.DE).

Earnings snapshot and market reaction: SRT3.DE stock

Sartorius reported results tied to a Q4 earnings announcement dated 03 Feb 2026. The market reacted with volume of 107,178 versus an average of 74,992, lifting relative volume to 1.4289. The stock opened at €239.90, hit a day high of €245.50, and a day low of €228.10, closing intraday at €230.90. The key market claim is this: the earnings miss focused attention on margin compression rather than top-line growth.

Financials and valuation: PE, EPS and leverage

Sartorius shows EPS €1.93 and a reported PE of 121.66 in the full quote. Book value per share is €55.24 and price-to-sales stands at 4.61. Net debt metrics are high: enterprise value is €20.09B against market cap €16.21B, and net debt to EBITDA reads 4.23. These ratios explain why valuation is sensitive to earnings surprises and cash flow guidance.

Meyka grade and model outlook

Meyka AI rates SRT3.DE with a score out of 100: 66.72, Grade B, suggestion HOLD. This grade factors in S&P 500 and sector comparison, sector performance, financial growth, key metrics, and analyst inputs. Meyka AI’s forecast model projects a monthly price of €215.80, implying nearer-term downside versus the current €230.90. Forecasts are model-based projections and not guarantees.

Guidance, cash flow and growth drivers

Management signalled cautious guidance after the quarter, citing mix shifts and higher operating costs. Operating cash flow per share is €10.54 and free cash flow per share is €4.80. R&D is 5.43% of revenue, supporting medium-term product expansion. The trade-off is clear: sustained top-line growth depends on margin recovery and successful rollout of higher-margin lab products.

Technicals and trading signals on XETRA

Technically, the 50-day average is €250.67 and the 200-day average is €221.99. RSI sits at 59.63, MACD histogram at 1.60, and ATR at 6.84, showing moderate momentum with elevated intraday volatility. Short-term traders will watch the €228.10 day low and the €245.50 high for breakout or support confirmation.

Risks and sector context for investors

Sartorius operates in Healthcare, Medical – Instruments & Supplies, a sector that has lagged broader indices. Sector norms show average PE near 33.39, while Sartorius carries a premium. Key risks include debt leverage, margin pressure, and inventory cycles. Opportunities include lab automation demand and higher-margin consumables that could restore earnings growth.

Final Thoughts

Key takeaways for SRT3.DE stock are straightforward. The intraday move to €230.90 on 03 Feb 2026 reflects a Q4 earnings miss and an emphasis on margin pressure over revenue surprises. Valuation is elevated with a reported PE of 121.66 and tight coverage ratios, while enterprise value over EBITDA is 21.91, highlighting sensitivity to earnings changes. Meyka AI’s forecast model projects a near-term level of €215.80, an implied downside of -6.54% versus the current price. A conservative 12-month baseline target of €200.00 assumes gradual margin recovery, while a bull case of €270.00 requires accelerating high-margin product sales. These figures are model projections and not guarantees. Given the mix of growth prospects and short-term earnings risk, our technical and fundamental read supports a cautious HOLD stance. For live charting and updates visit Meyka AI’s stock page for SRT3.DE

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.